Kliniske retningslinier for udredning af cancer thyroidear 2009, udkast
Kliniske retningslinier for udredning af cancer thyroidear 2009, udkast Kliniske retningslinier for udredning af cancer thyroidear 2009, udkast
Thyreoideacancer – udkast Kliniske retningslinier – revision – juni 2009 cancer. J Surg.Oncol 2007;96:173-5. 186. Travagli JP, Cailleux AF, Ricard M, Baudin E, Caillou B, Parmentier C et al. Combination of radioiodine (131I) and probe-guided surgery for persistent or recurrent thyroid carcinoma. J Clin Endocrinol.Metab 1998;83:2675-80. 187. Rubello D, Salvatori M, Ardito G, Mariani G, Al Nahhas A, Gross MD et al. Iodine-131 radio-guided surgery in differentiated thyroid cancer: outcome on 31 patients and review of the literature. Biomed.Pharmacother. 2007;61:477-81. 188. Negele T, Meisetschlager G, Bruckner T, Scheidhauer K, Schwaiger M, Vogelsang H. Radio-guided surgery for persistent differentiated papillary thyroid cancer: case presentations and review of the literature. Langenbecks Arch.Surg. 2006;391:178-86. 189. Travagli JP, Cailleux AF, Ricard M, Baudin E, Caillou B, Parmentier C et al. Combination of radioiodine (131I) and probe-guided surgery for persistent or recurrent thyroid carcinoma. J Clin Endocrinol.Metab 1998;83:2675-80. 190. Grant CS, Grant. Medullary thyroid carcinoma and associated multiple endocrine neoplasia type 2. In: Hay ID, Wass JA. Clinical endocrine oncology, Second Edition ed. Massachusetts: Blackwell Publishing, 2008:515-22. 191. Gimm O, Ukkat J, Dralle H. Determinative factors of biochemical cure after primary and reoperative surgery for sporadic medullary thyroid carcinoma. World J.Surg. 1998;22:562-7. 192. Kebebew E, Kikuchi S, Duh QY, Clark OH. Long-term results of reoperation and localizing studies in patients with persistent or recurrent medullary thyroid cancer. Arch.Surg. 2000;135:895-901. 193. Moley JF, Dilley WG, Debenedetti MK. Improved results of cervical reoperation for medullary thyroid carcinoma. Ann.Surg. 1997;225:734-40. 194. Moley JF, Dilley WG, Debenedetti MK. Improved results of cervical reoperation for medullary thyroid carcinoma. Ann.Surg. 1997;225:734-40. 195. Gimm O, Dralle H. Reoperation in metastasizing medullary thyroid carcinoma: is a tumor stageoriented approach justified? Surgery 1997;122:1124-30. 196. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N.Engl.J.Med. 2008;359:31-42. 197. Andersen, P. H., Kroustrup, J. P., Feldt-Rasmussen, U. F., Hangaard, J., and Brixen, K. Multipel endokrin neoplasi. Andersen, P. H., Kroustrup, J. P., Feldt-Rasmussen, U. F., Hangaard, J., and Brixen, K. 1-12. 2002. København, Lægeforeningens Forlag. Klaringsrapport. Ref Type: Report 198. Eng C, Smith DP, Mulligan LM, Nagai MA, Healey CS, Ponder MA et al. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum.Mol.Genet. 1994;3:237-41. 199. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum.Mol.Genet. 1993;2:851-6. 200. Hofstra RM, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994;367:375-6. 64
Thyreoideacancer – udkast Kliniske retningslinier – revision – juni 2009 201. Lips CJ, Landsvater RM, Hoppener JW, Geerdink RA, Blijham G, van VJ et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A [see comments]. N.Engl.J.Med. 1994;331:828-35. 202. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J.Clin.Endocrinol.Metab 2001;86:5658-71. 65
- Page 13 and 14: TNM-KLASSIFIKATION Thyreoideacancer
- Page 15 and 16: Thyreoideacancer - udkast Kliniske
- Page 17 and 18: Thyreoideacancer - udkast Kliniske
- Page 19 and 20: Thyreoideacancer - udkast Kliniske
- Page 21 and 22: Thyreoideacancer - udkast Kliniske
- Page 23 and 24: Thyreoideacancer - udkast Kliniske
- Page 25 and 26: Thyreoideacancer - udkast Kliniske
- Page 27 and 28: Thyreoideacancer - udkast Kliniske
- Page 29 and 30: Akut sialoadenitis Thyreoideacancer
- Page 31 and 32: Thyreoideacancer - udkast Kliniske
- Page 33 and 34: Thyreoideacancer - udkast Kliniske
- Page 35 and 36: Thyreoideacancer - udkast Kliniske
- Page 37 and 38: Thyreoideacancer - udkast Kliniske
- Page 39 and 40: Substitutionsdosis Thyreoideacancer
- Page 41 and 42: Thyreoideacancer - udkast Kliniske
- Page 43 and 44: Thyreoideacancer - udkast Kliniske
- Page 45 and 46: PATIENTINFORMATION Hvad er skjoldbr
- Page 47 and 48: Thyreoideacancer - udkast Kliniske
- Page 49 and 50: Kontrol og prognose Thyreoideacance
- Page 51 and 52: Thyreoideacancer - udkast Kliniske
- Page 53 and 54: Thyreoideacancer - udkast Kliniske
- Page 55 and 56: Thyreoideacancer - udkast Kliniske
- Page 57 and 58: Am.J.Surg.Pathol. 1997;21:754-62. T
- Page 59 and 60: Thyreoideacancer - udkast Kliniske
- Page 61 and 62: Thyreoideacancer - udkast Kliniske
- Page 63: Thyreoideacancer - udkast Kliniske
Thyreoidea<strong>cancer</strong> – <strong>udkast</strong> <strong>Kliniske</strong> <strong>retningslinier</strong> – revision – juni <strong>2009</strong><br />
<strong>cancer</strong>. J Surg.Oncol 2007;96:173-5.<br />
186. Travagli JP, Cailleux AF, Ricard M, Baudin E, Caillou B, Parmentier C et al. Combination of radioiodine<br />
(131I) and probe-guided surgery <strong>for</strong> persistent or recurrent thyroid carcinoma. J Clin Endocrinol.Metab<br />
1998;83:2675-80.<br />
187. Rubello D, Salvatori M, Ardito G, Mariani G, Al Nahhas A, Gross MD et al. Iodine-131 radio-guided<br />
surgery in differentiated thyroid <strong>cancer</strong>: outcome on 31 patients and review of the literature. Biomed.Pharmacother.<br />
2007;61:477-81.<br />
188. Negele T, Meisetschlager G, Bruckner T, Scheidhauer K, Schwaiger M, Vogelsang H. Radio-guided<br />
surgery <strong>for</strong> persistent differentiated papillary thyroid <strong>cancer</strong>: case presentations and review of the literature.<br />
Langenbecks Arch.Surg. 2006;391:178-86.<br />
189. Travagli JP, Cailleux AF, Ricard M, Baudin E, Caillou B, Parmentier C et al. Combination of radioiodine<br />
(131I) and probe-guided surgery <strong>for</strong> persistent or recurrent thyroid carcinoma. J Clin Endocrinol.Metab<br />
1998;83:2675-80.<br />
190. Grant CS, Grant. Medullary thyroid carcinoma and associated multiple endocrine neoplasia type 2. In:<br />
Hay ID, Wass JA. Clinical endocrine oncology, Second Edition ed. Massachusetts: Blackwell Publishing,<br />
2008:515-22.<br />
191. Gimm O, Ukkat J, Dralle H. Determinative factors of biochemical cure <strong>af</strong>ter primary and reoperative<br />
surgery <strong>for</strong> sporadic medullary thyroid carcinoma. World J.Surg. 1998;22:562-7.<br />
192. Kebebew E, Kikuchi S, Duh QY, Clark OH. Long-term results of reoperation and localizing studies in<br />
patients with persistent or recurrent medullary thyroid <strong>cancer</strong>. Arch.Surg. 2000;135:895-901.<br />
193. Moley JF, Dilley WG, Debenedetti MK. Improved results of cervical reoperation <strong>for</strong> medullary thyroid<br />
carcinoma. Ann.Surg. 1997;225:734-40.<br />
194. Moley JF, Dilley WG, Debenedetti MK. Improved results of cervical reoperation <strong>for</strong> medullary thyroid<br />
carcinoma. Ann.Surg. 1997;225:734-40.<br />
195. Gimm O, Dralle H. Reoperation in metastasizing medullary thyroid carcinoma: is a tumor stageoriented<br />
approach justified? Surgery 1997;122:1124-30.<br />
196. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG et al. Motesanib diphosphate in<br />
progressive differentiated thyroid <strong>cancer</strong>. N.Engl.J.Med. 2008;359:31-42.<br />
197. Andersen, P. H., Kroustrup, J. P., Feldt-Rasmussen, U. F., Hangaard, J., and Brixen, K. Multipel endokrin<br />
neoplasi. Andersen, P. H., Kroustrup, J. P., Feldt-Rasmussen, U. F., Hangaard, J., and Brixen, K.<br />
1-12. 2002. København, Læge<strong>for</strong>eningens Forlag. Klaringsrapport.<br />
Ref Type: Report<br />
198. Eng C, Smith DP, Mulligan LM, Nagai MA, Healey CS, Ponder MA et al. Point mutation within the<br />
tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related<br />
sporadic tumours. Hum.Mol.Genet. 1994;3:237-41.<br />
199. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC et al. Mutations in the RET<br />
proto-oncogene are associated with MEN 2A and FMTC. Hum.Mol.Genet. 1993;2:851-6.<br />
200. Hofstra RM, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y et al. A mutation in the RET<br />
proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid<br />
carcinoma. Nature 1994;367:375-6.<br />
64
Change language